Literature DB >> 10626229

Cancer-prone oxyradical overload disease.

S Ambs1, S P Hussain, A J Marrogi, C C Harris.   

Abstract

Oxyradical overload disease develops in conditions involving chronic inflammation and may be of inherited etiology, e.g. haemochromatosis and Wilson disease, be acquired, e.g. infection with hepatitis B or C virus or Helicobactor pylori, or be chemically induced, e.g. acid reflux in Barrett oesophagus. Susceptibility to cancer is frequently a pathological consequence of extensive oxyradical damage that leads to a cycle of cell death and regeneration and causes mutations in cancer-related genes. In this brief review, we focus on the possible interactive effects of nitric oxide and the p53 tumour suppressor gene in human carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626229

Source DB:  PubMed          Journal:  IARC Sci Publ        ISSN: 0300-5038


  8 in total

1.  Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases.

Authors:  S P Hussain; K Raja; P A Amstad; M Sawyer; L J Trudel; G N Wogan; L J Hofseth; P G Shields; T R Billiar; C Trautwein; T Hohler; P R Galle; D H Phillips; R Markin; A J Marrogi; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 2.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

3.  Graft-versus-host disease: role of inflammation in the development of chromosomal abnormalities of keratinocytes.

Authors:  Elaine M Sloand; Loretta Pfannes; Casey Ling; Xingmin Feng; Monika Jasek; Rodrigo Calado; Zachary C G Tucker; Peiman Hematti; Jaroslaw Maciejewski; Cynthia Dunbar; John Barrett; Neal Young
Journal:  Biol Blood Marrow Transplant       Date:  2010-07-24       Impact factor: 5.742

Review 4.  Clinical outcomes and correlates of TP53 mutations and cancer.

Authors:  Ana I Robles; Curtis C Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03       Impact factor: 10.005

Review 5.  Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.

Authors:  Christopher H Switzer; Sharon A Glynn; Lisa A Ridnour; Robert Y-S Cheng; Michael P Vitek; Stefan Ambs; David A Wink
Journal:  Trends Pharmacol Sci       Date:  2011-09-04       Impact factor: 14.819

Review 6.  tRNA modifications regulate translation during cellular stress.

Authors:  Chen Gu; Thomas J Begley; Peter C Dedon
Journal:  FEBS Lett       Date:  2014-10-07       Impact factor: 4.124

Review 7.  Disruptive chemicals, senescence and immortality.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Hiroshi Kondoh; Matilde E Lleonart; Juan Fernando Martinez-Leal; Chiara Mondello; A Ivana Scovassi; William H Bisson; Amedeo Amedei; Rabindra Roy; Jordan Woodrick; Annamaria Colacci; Monica Vaccari; Jayadev Raju; Fahd Al-Mulla; Rabeah Al-Temaimi; Hosni K Salem; Lorenzo Memeo; Stefano Forte; Neetu Singh; Roslida A Hamid; Elizabeth P Ryan; Dustin G Brown; John Pierce Wise; Sandra S Wise; Hemad Yasaei
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

8.  Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease.

Authors:  Yildiz Dincer; Yusuf Erzin; Solen Himmetoglu; Kezban Nur Gunes; Kadir Bal; Tülay Akcay
Journal:  Dig Dis Sci       Date:  2007-03-29       Impact factor: 3.487

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.